[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.114.118. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
March 7, 2001

Talking With Alan I. Leshner, PhD, National Institute on Drug Abuse Director

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;285(9):1141-1143. doi:10.1001/jama.285.9.1141

Bethesda, Md—Since Alan I. Leshner, PhD, took the helm of the National Institute on Drug Abuse (NIDA) in 1994, the agency's annual budget has nearly doubled, to $781 million, supporting much of the world's research on the biology of addiction, genetic and environmental risk factors, and addiction prevention and treatment.

Of the two dozen institutes that comprise the National Institutes of Health (NIH), NIDA is in a unique position. Addiction is, arguably, more politicized than any other medical issue, putting Leshner and his views under a spotlight. He is quoted almost weekly in major newspaper and magazine articles as the authority on the subject. Such visibility comes with a price, though, as Leshner has been attacked on all fronts—for being both too soft and too harsh on drug issues.

First Page Preview View Large
First page PDF preview
First page PDF preview
×